Ask Warren

Remed

302550 · KOSDAQ · ₩302550 · 리메드

₩2,290▲ ₩75 (3.39%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩7.4B₩7.2B₩6.7B₩5.8B₩5.6B₩6.4B₩6.4B₩6B
Cost of sales₩3.2B₩3.1B₩3.2B₩2.3B₩2.3B₩2.6B₩2.7B₩2.7B
Gross profit₩4.1B₩4.1B₩3.5B₩3.5B₩3.2B₩3.9B₩3.8B₩3.4B
Operating income₩945M₩684M₩51M₩272M₩25M₩377M−₩250M₩124M
Net income−₩746M₩1B−₩203M₩385M−₩435M₩218M₩3.9B₩2.5B
Net income to shareholders₩701M₩1.1B−₩211M₩445M−₩163M₩455M₩2.5B₩3.6B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩54B₩55B₩54B₩55B₩54B₩57B₩59B₩65B
Current assets₩27B₩29B₩28B₩30B₩29B₩31B₩29B₩32B
Cash and equivalents₩9B₩10B₩8.5B₩7.2B₩6.1B₩4.7B₩5.7B₩7.4B
Total liabilities₩17B₩16B₩14B₩15B₩14B₩16B₩19B₩28B
Current liabilities₩11B₩10B₩9.5B₩10B₩11B₩14B₩9B₩18B
Borrowings₩1.5B₩1.1B₩1.1B₩1.7B₩2B₩3.1B₩3.1B₩5.8B
Total equity₩37B₩39B₩39B₩40B₩41B₩41B₩40B₩38B
Shareholders' equity₩38B₩40B₩40B₩41B₩41B₩41B₩40B₩38B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations₩1.7B₩239M₩1B−₩279M₩539M₩1.1B−₩4.3B₩3.6B
Free cash flow₩1.7B₩239M₩1B−₩279M₩539M₩1.1B−₩4.3B₩3.6B

Consolidated where available. Amounts in won.

Also known as: Remed / 리메드 / 302550 / KRX:302550

Source: KRX statistical information